YourHealthRx Review

The first-month price is not the price

The rate YourHealthRx advertises is a discounted introductory month. The ongoing monthly rate is higher. That is the first thing to understand here, and the reason a casual comparison will get it wrong. The figures shown on this page are the ongoing rates — what a patient lives with from month two onward — and the qualifier beside each one says so.

An introductory rate set against a competitor's standing rate produces a gap that does not exist, and the reader only finds out once switching has become inconvenient. A first-month discount is a marketing instrument, not a price. Treating it as one in a comparison table is how a reader ends up paying more than they planned for a year.

None of which makes the discount bad. It lowers the cost of finding out whether treatment suits you, which has real value. It is just not the number to budget against, and any comparison that leads with it is doing the provider's work rather than the reader's.

What the price does hold steady on

Once a patient is on the ongoing rate, that rate holds steady while the dose climbs. Dose-tiered pricing is the quiet trap in this category, since the bill climbs at exactly the point the medication starts working. YourHealthRx does not have it. Bloodwork and follow-up appointments are folded into the program instead of sold as extras, which removes the other common source of drift between a headline figure and an actual annual cost.

So the structure past month one is reasonably clean. It is the transition from month one to month two that a reader needs to have priced correctly, and the qualifier on every figure exists to make sure they have.

A nationwide network, and two ways to take it

YourHealthRx works with a clinician network licensed across all fifty states and DC through the Interstate Medical Licensure Compact. State availability is not the obstacle here that it is with several providers in this comparison. A reader in a smaller market can proceed without checking a coverage map first.

Both compounds are available as a weekly injection or as a daily dissolving tablet. That choice is uncommon in this set, and it matters for the substantial group of readers whose objection to GLP-1 treatment is the needle rather than the cost. YourHealthRx also carries a broader catalog of longevity peptides beyond the GLP-1 line. That is either a reason to consolidate or a reason to look elsewhere, depending on whether you want a focused weight-management program or a wider pharmacy relationship.

Who you are actually contracting with

YourHealthRx presents itself as the technology and commerce layer. Deciding who qualifies and writing the prescription happen inside partner clinical operations, not at YourHealthRx. That structure is common in telehealth and is not itself a defect. It does change who a patient is dealing with when something goes wrong. Readers routinely miss it until they need to escalate a problem and discover the company they paid is not the company that made the clinical decision.

Ask during intake who is responsible for what. Who reviews eligibility, who signs the prescription, who to contact about a side effect, and who to contact about a shipment. Those may be three different answers, and on a platform model they usually are. Knowing them in advance is the difference between a five-minute call and a week of being passed between parties.

What is not disclosed

YourHealthRx never identifies the pharmacy that compounds and dispenses the medication, and the site carries no LegitScript seal. Both matter more on a platform model than they would elsewhere. The platform layer already puts distance between the patient and the parties doing the clinical and dispensing work. Add an unnamed pharmacy to that, and a reader cannot identify anyone in the chain except the company that took the payment.

The products in this category at YourHealthRx are compounded. Compounded semaglutide and tirzepatide are prepared by a compounding pharmacy and are not FDA-approved finished drug products. YourHealthRx does not publish a brand-name option, so a reader who wants an approved medication is comparing the wrong set of providers.